Overview of Drug Allergy: From Immunogenetic Basis to Practice

Alergia a Fármacos: Da Imunogenética à Clínica

Eunice DIAS DE CASTRO, Fabrícia CAROLINO, Laura RIBEIRO, Josefina R. CERNADAS

ABSTRACT

Drug therapy is often a balance between the beneficial and harmful effects of drugs. Drug allergic reactions are adverse reactions mediated by immunological mechanisms and usually not related to the pharmacological actions of the drug. They can be classified based either on the clinical presentation or the underlying immunological mechanism. Although uncommon, drug allergic reactions are unpredictable and can be very severe, even life threatening. The aim of this review was to provide clinicians from different medical specialties with a working tool to improve management of their patients with suspected drug allergy. It was conducted as a non-systematic review, and attempts to describe the complexity of drug allergy. The information included ranges from pathophysiology to the heterogeneous clinical presentation, with a special focus on the drugs most frequently involved, as well as a classification of reactions and risk factors. Despite all advances in this challenging and complex field of allergy and clinical immunology, drug allergy is not yet fully established and understood. An exceptional contribution was brought by pharmacogenomics, even though a specific pharmacogenetic association has only been defined for a very limited number of drugs. Further studies are needed to obtain clearer answers when managing each individual case of drug allergy.

Keywords: Drug Hypersensitivity/etiology; Drug Hypersensitivity/immunology; Pharmacogenetics; Drug-Related Side Effects and Adverse Reactions

RESUMO

A terapêutica farmacológica consiste, frequentemente, num equilíbrio entre os efeitos benéficos e prejudiciais dos fármacos. As reações alérgicas a fármacos são reações adversas mediadas por mecanismos imunológicos e não relacionadas com as ações farmacológicas do fármaco. Podem ser classificadas quer com base na apresentação clínica, quer no mecanismo imunológico subjacente. Embora pouco comuns, as reações alérgicas a fármacos são imprevisíveis, podendo ser graves e potencialmente fatais. O objetivo da presente revisão foi disponibilizar aos médicos de diversas áreas médicas uma ferramenta de trabalho para um melhor abordagem dos seus doentes com suspeita de alergia a fármacos. Foi conduzida de forma não sistemática e procura descrever a complexidade das reações alérgicas a fármacos, desde a fisiopatologia à heterogeneidade da apresentação clínica. Foi dado especial destaque aos fármacos mais frequentemente envolvidos, à classificação das reações e aos fatores de risco. Apesar de todos os avanços nesta área desafiante e complexa da alergologia e imunologia clínica, a alergia a fármacos não está ainda completamente compreendida e estabelecida. A farmacogenética trouxe um contributo excepcional, embora apenas para um número muito limitado de fármacos esteja definida uma associação farmacogenética. São necessários estudos adicionais que permitam obter respostas mais diretas na abordagem de cada caso individual de alergia a fármacos.

Palavras-chave: Efeitos Colaterais e Reações Adversas Relacionados a Medicamentos; Farmacogenética; Hipersensibilidade a Medicamentos/etiologia; Hipersensibilidade a Medicamentos/imunologia

INTRODUCTION

Drug therapy is often a balance between the beneficial and harmful effects of drugs. Despite the intensive research in the field, adverse drug reactions (ADRs) remain a major problem. An ADR has been defined by the World Health Organization as any noxious, unintended and undesired effect of a drug occurring at doses normally used for prevention, diagnosis or treatment. It has been estimated that ADRs account for 3% to 6% of all hospital admissions and occur in 10% to 15% of hospitalized patients, contributing to morbidity and mortality. A widely used classification system divides ADRs in type A (predictable, common, related to the pharmacological properties of the drug), and type B (unpredictable, uncommon, unrelated to the pharmacological actions of the drug). The first type comprises approximately 80% of all ADRs and includes drug-induced toxicity, side effects and drug interactions. Drug allergic reactions (DARs) are those mediated by immunological mechanisms and belong to type B. In practice, based on the clinical presentation alone, it is often difficult to differentiate between immune and non-immune mediated reactions. Therefore, the term drug hypersensitivity is applied when an immunological mechanism cannot be demonstrated in drug reactions that clinically look like allergic. Drug hypersensitivity reactions (DHRs) comprise 15% of all ADR. DARs, although less common (estimated to represent a small percentage of all ADRs), can be very complex and potentially severe, even life-threatening. The study of DARs is challenging and is constantly updated as new drugs are developed and drug consumption patterns are changed.
The aim of this review of the current literature was to provide clinicians from different medical specialties with a working tool to improve management of their patients with suspected drug allergy (DA). It was conducted as a non-systematic review, and attempts to describe the complexity of DA. The information included ranges from pathophysiology to clinical presentation, with a special focus on the drugs most frequently involved, as well as classification of reactions and risk factors.

1 – Classification

A consensus classification is mandatory to guide and validate the diagnostic work-up. DARs can be classified based on the clinical presentation or the underlying immunological mechanism (Table 1).

Clinically, DARs are classified depending on the time elapsed between drug administration and the onset of symptoms: immediate (usually occurring up to one hour; could be between 1 to 6 hours: accelerated reactions) and non-immediate (at any time, after one hour and up to several days of drug administration).4

Any of the four immunologic mechanisms proposed by Gell and Coombs may underlie DARs, being the IgE and T-cell-mediated the most common.4,9 Type I, also known as immediate reactions (IRs), are mediated by drug-specific IgE antibodies. Type II (cytotoxic) and Type III (immune complex) are mediated by drug-specific IgG or IgM antibodies. Type IV are mediated primarily by T cells4,6,9,12 and have been recently classified in 4 subtypes, according to cytokine patterns and the preferential activation of different immunocytes.9

2 – Clinical Presentation

2.1 – Immediate reactions (IRs): IRs present as isolated symptoms (urticaria, angioedema, conjunctivitis, rhinitis, bronchospasm) or as a severe reaction such as anaphylaxis. Urticaria/angioedema and anaphylaxis are the most common. The IgE-mediated allergy to β-Lactam (βL) antibiotics is the paradigmatic example.4,13,14

2.2 – Non-immediate reactions (NIRs): The skin is the most frequently involved organ, with a wide range of clinical presentations. Maculopapular exanthema (MPE) and delayed urticaria are the most common.4,6,10,13 Fixed drug eruption (FDE), acute generalized exanthematic pustulosis (AGEP), erythema multiforme (EM) and eczema are other presentations.12

Both skin and other organs can be involved, as in drug rash with eosinophilia and systemic symptoms (DRESS)/drug-induced hypersensitivity syndrome (DiHS), vasculitis and Stevens-Johnson syndrome (SJS)/toxic epidermal necrolysis (TEN).4,6,10,13.

Mild eruptions usually occur one to few days after the drug treatment is started, while most severe reactions often

<table>
<thead>
<tr>
<th>Type</th>
<th>Type of immune response</th>
<th>Pathophysiology</th>
<th>Timing of reaction</th>
<th>Clinical symptoms</th>
<th>Typical chronology of the reaction</th>
</tr>
</thead>
<tbody>
<tr>
<td>I</td>
<td>IgE</td>
<td>Mast cell and basophil degranulation</td>
<td>Immediate</td>
<td>Anaphylaxis</td>
<td>Immediate, usually up to one hour, but could occur between 1h to 6h after the last drug intake</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Urticaria/Angioedema</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Bronchospasm</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Rhinitis</td>
<td></td>
</tr>
<tr>
<td>II</td>
<td>IgG and complement</td>
<td>IgG and complement-dependent cytotoxicity</td>
<td>Non-immediate</td>
<td>Cytopenia</td>
<td>5 – 15 days after the start of the eliciting drug</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Serum sickness</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Urticaria</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Vasculitis</td>
<td></td>
</tr>
<tr>
<td>III</td>
<td>IgM or IgG and complement or FcR</td>
<td>Deposition of immune complexes</td>
<td>Non-immediate</td>
<td>Eczema</td>
<td>1 – 21 days after the start of the eliciting drug</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>IV a</td>
<td>Th1 (IFN-gamma)</td>
<td>Monocytic inflammation</td>
<td>Non-immediate</td>
<td></td>
<td>1 to several days after the start of the eliciting drug for MPE; 2 – 6 weeks for DRESS/DiHS</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>IV b</td>
<td>Th2 (IL-4 and IL-5)</td>
<td>Eosinophilic inflammation</td>
<td>Non-immediate</td>
<td></td>
<td>1 – 2 days after the start of the eliciting drug for FDE; 4 – 28 days for SJS/TEN</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>IV c</td>
<td>Cytotoxic T cells (perforin, granzyme B, FasL, granulysin)</td>
<td>Keratinocytic death mediated by CD4 or CD8</td>
<td>Non-immediate</td>
<td></td>
<td>1 – 2 days after the start of the eliciting drug, but can be longer</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>IV d</td>
<td>T cells (IL-8/CXCL8)</td>
<td>Neutrophilic inflammation</td>
<td>Non-immediate</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

IgE: Immunoglobulin E; IgM: Immunoglobulin M; IgG: Immunoglobulin G; Th1: T helper1; Th2: T helper 2; IFN gamma: Interferon gamma; IL4: Interleukin 4; IL5: Interleukin 5; IL8: Interleukin 8; CXCL8: Chemokine motif ligand 8; MPE: Maculopapular exanthema; DRESS: Drug rash with eosinophilia and systemic symptoms; DiHS: Drug-induced hypersensitivity syndrome; FDE: Fixed drug eruption; SJS: Stevens-Johnson syndrome; TEN: Toxic epidermal necrolysis; AGEP: Acute generalized exanthematic pustulosis.
begin later on (SJS/TEN: 4 - 21 days; DRESS/DiHS: 2 - 6 weeks).4

DRESS is an unusual DAR characterized by the presence of morbilliform rash, atypical lymphocytosis, eosinophilia, fever and other organ involvement, usually liver.12,15 A minimum criterion of rash, fever, hepatitis and lymphocytosis has been proposed for DiHS.16

SJS and TEN, the most severe type of reactions affecting the skin, are characterized by extensive epidermal detachment and mucous membrane erosion, including oral, conjunctival and anal.10,12 Although uncommon (estimated prevalence: 5 - 6 cases and 1 - 2 cases per million patients for SJS and TEN, respectively),17 the morbidity and mortality is high (5% - 10% mortality for SJS16,17 and 30% - 50% for TEN).12,16-18 Several authors support that SJS and TEN are a single disease with common causes and physiopathology, but different spectrums of severity according to the extension of epidermal detachment (< 10% : SJS; 10% – 30% : SJS – TEN overlapping; > 30% : TEN).10,12,16-18 Drugs causing SJS/TEN overlap with those causing DRESS/DiHS: aromatic amine anticonvulsants, sulfonamides antibiotics, nonsteroidal anti-inflammatory drug (NSAIDs) and antiretroviral agents. Allopurinol and lamotrigine were also associated with SJS/TEN.10,12,16,17

EM is characterized by the presence of target-shaped lesions and, although less severe, can be an early presentation of SJS/TEN. Any of these reactions contraindicate the re-administration of the culprit drug.12

3 – Pathogenesis and Physiopathology

3.1 – Chemical basis: For a drug to become an antigen able to elicit an immune response, two main mechanisms have been proposed: 1. The drug, a chemically reactive small-molecule, must bind irreversibly to a protein, generating antigens (hapten concept); 2. The drug, chemically inert, needs to be converted into reactive metabolites before binding irreversibly to proteins (pro-hapten concept).4,5,10,19,22

For T-cell mediated reactions, the role of a carrier-protein/hapten has not been fully defined as it has been for IgE-mediated reactions.4,19

An alternative hypothesis is that some drugs might also originate a direct reversible interaction with the T-cell receptors or HLA-molecules, activating T cells by pharmacological interaction (p-i concept).9 According to this hypothesis, the drug eliciting an immunological response is not dependent on its structural features nor metabolism. Chemically inert drugs are able to directly activate T-cell receptors.4,5,11,20,21

Cross-reactivity between drugs is an immunological reaction that occurs on exposure to different drugs with a similar molecular structure. This can happen even without any previous exposure to the cross-reacting drug, allowing to predict, to some extent, the risk of reactivity to chemically related drugs.11

3.2 – Immunopathological mechanisms: It has been proposed that drug-protein conjugates might be processed and presented by antigen-presenting cells to naive T cells, after drug intake, inducing tolerance or effector responses.24 In the last case, the immune system develops either immediate T-helper2 (Th2)-type responses, mediated by specific IgE antibodies, or non-immediate Th1-type responses, mainly mediated by specific T cells.5,10 Alternatively, T cells could be directly stimulated by the drug.9

3.2.1 – Immediate reactions: IRs develop as a result of IgE production. At an initial sensitization phase, B-cells proliferate and differentiate into plasma cells, in the presence of specific Th2-cells. Drug-specific IgE are then produced and bind to the high-affinity FcRI receptors on the surface of mast cells and basophils. On subsequent drug exposure, the drug antigen cross-links IgE on the surface of mast cells, activating them and inducing the release of preformed mediators (e.g., histamine, tryptase, TNF-α) and the production of new ones (e.g., leukotrienes, prostaglandins, cytokines). The sensitization phase is usually asymptomatic and may have occurred during an earlier drug treatment.4,5

3.2.2 – Non-immediate reactions: The majority are mediated by T lymphocytes.4 Most of the information available relates to the specific effector immune response mediated by T cells. Little is known about the initial steps mediated by the innate immune system, mainly by dendritic cells.10,23 It has been proposed that these cells can process the drug antigen as a first step to stimulate naive T cells.4 The antigen is internalized and transported to the regional lymph nodes, where it is presented to naive T cells. Alternatively, it may stimulate directly pathogen-specific T cells, without priming by dendritic cells. Antigen-specific T cells migrate to target organs and on re-exposure to the drug, are activated to secrete cytokines.

Other immune cells are involved in NIRS, fitting into the four subtypes of Type IV reactions4: (Ia), Th1 cells produce interferon-γ-activated macrophages, typically in eczema; (Ib), Th2 cytokines induce the production of antibodies by B cells and the eosinophil responses, mainly in MPE and DRESS; (Ic), CD4+ and CD8+ T cells produce cytotoxic mediators leading to keratinocyte apoptosis in MPE and massive apoptosis in SJS/TEN; (Id), neutrophil recruitment and T-cell-induced activation by the production of a chemokine, CXCL8, mainly in AGEP.

The histopathology findings in SJS/TEN show detachment of a large portion of the epidermis.12 Previously, Fas-FasL interaction and perforin-granzyme B were the pathways reported as basic effectors.12,16 More recently, granzym B was described as a key effector responsible for the death of keratinocytes.16,18,24 Granulysin concentrations in blister fluid seem to correlate with the severity of SJS/TEN24 and high granulysin serum levels may be a useful early diagnostic biomarker.18

In a minority of NIRS other immune mechanisms may be involved. Type II reactions concern IgG-mediated cytotoxicity directed to membranes of erythrocytes, leukocytes and platelets. Drugs typically involved are methyldopa (hemolytic anemia), aminopyrine (leukopenia), and heparin (thrombocytopenia). Such reactions may occur only as long as the drug is present in soluble form. Type III reactions
involve the formation of immune complexes (IC), a common event in a normal immune response, usually asymptomatic. On rare occasions, IC bind to endothelial cells and lead to IC deposition with complement activation in small blood vessels, resulting in serum sickness syndrome (SSS), drug-induced lupus erythematosus or vasculitis.

3.3 – Pharmacogenetics: The discovery of strong associations between certain severe reactions, mostly NIRs, and HLA-B alleles has allowed a great progress in DA. The association of HLA alleles with SJS/TEN has been reported, for the first time, more than 25 years ago. Since then, specific HLA alleles have been found to be associated with this disease. A strong association between carbamazepine (CBZ)-induced SJS/TEN and HLA-B*1502 has been described in a Chinese population, where this allele was present in all patients suffering from CBZ-induced SJS. Subsequently this association was also found in Indian and Thai, but not in Japanese nor in European patients. This association seems to be phenotype-specific (SJS/TEN) and is stronger than any other described so far.

In northern Europeans, the presence of HLA-A*3101 has been associated with a wide spectrum of CBZ-induced reactions (MPE, DRESS/DiHS, SJS/TEN). Other important association include HLA-B*5801 and SJS/TEN or DRESS/DiHS with allopurinol, in Asian and European populations.

Finally, the carriage of HLA-B*5701 has been strongly associated with flucloxacillin-induced liver injury and with abacavir hypersensitivity syndrome, a severe multi-organic reaction. This association was higher among Caucasians, where the allele was present in 94.4% cases (positive predictive value ≥ 70%; negative predictive value: 95% - 98%). International HIV treatment guidelines recommend the HLA-B*5701 screening prior to the abacavir treatment.

Recent pharmacogenomic studies evolving from a candidate-gene approach to the genome-wide association study (GWAS) brought great advances in the discovery of genes associated with inter-individual differences in drug response (mainly genes predisposing to ADRs but also genes responsible for drug efficacy). The HLA system has been a major focus for type B reactions, particularly the more severe immune reactions. A number of polymorphisms located on chromosome 6 have been found in association with SJS/TEN induced by allopurinol and abacavir. In IRs, some polymorphisms in cytokine genes have been weakly associated with BL-induced anaphylaxis.

This greater knowledge has made some DARs quite predictable.

3.4 – Risk factors: There are few identified factors influencing the risk of sensitization and the severity of DARs. These are the chemical structure of the molecule, the nature of drug exposure (dose, route, frequency and duration), the presence of co-factors (e.g. stress, infections), genetic predisposition, immune status and female gender.

the balance between drug and individual factors (Fig. 1), a disturbed immunologic status associated with the development of recurrent infections, decreases the threshold to induce a response. Moreover, the HLA genotype can dictate the way in which a drug can cause allergy.

Anaphylaxis has been associated with certain drugs (NSAIDs, radiocontrast media, antibiotics, opioids, peri-operative drugs) in patients with mast cell disorders. However, data are scarce and evidence for an association is limited. Nevertheless, mastocytosis should be ruled out in cases of severe anaphylaxis.

3.4.1 – The role of viruses: Viral infections are the main cause of skin reactions that can mimic DARs if the drug, usually an antibiotic, is taken simultaneously. Viruses can also interact with drugs and immune system, leading to allergic reactions such as the mild ampicillin exanthema associated with viral infection and has been linked to the reactivation of human herpes virus (HHV)-6. EBV, cytomegalovirus and other HHV, even days or weeks after the discontinuation of the drug.

The interaction with the immune system can occur at several points: drug metabolism; drug presentation to T cells, by dendritic cells; and effector response (cytokine and chemokine production).

4 – Allergic reactions to specific drugs

4.1 – Antibiotics

4.1.1 – β-Lactams: βLs are still the most frequent cause of DARs. Benzylpenicillin was the first βL implicated, but amoxicillin has progressively become the most common culprit. A wide range of manifestations can occur, reflecting different underlying immunological mechanisms. They can induce IRs, mediated by IgE (usually urticaria/angioedema and anaphylaxis) and also NIRs (mainly MPE). Severe NIRs (AGEP, SJS/TEN, DRESS) can also occur.

Figure 1 – Drug Allergy: a balance between drug factors and patient biology (adapted from 21)
βLs clearly induce immunological reactions due to hapten-carrier formation which occur through the nucleophilic opening of the βL ring and the generation of reactive intermediates.6,13,22 Recent studies have pointed out the relevance of the three-dimensional shape of the βL, as well as its inherent chemical reactivity, in determining the selectivity of the covalent binding.20 The role of side chains that distinguish different penicillin compounds as relevant allergenic determinants is also widely accepted, particularly in IRs to aminopenicillins and cephalosporins. Thus, cephalosporins with a similar side-chain should be avoided in patients with IgE-mediated reactions to penicillin.13,40 Moreover, in cases of IRs to penicillin, skin testing with alternative drugs (cephalosporins, carbapenems, aztreonam) is recommended prior to its administration. If negative, the drug should be given by increasing doses in an appropriate setting.13

In NIRs to aminopenicillins, both core structure and the whole molecule (core structure plus the amino-benzyl group of the side-chain) are recognized by T cells, although the latter plays a predominant role.13 Despite the fact that cross-reactivity between penicillins, cephalosporins and carbapenems for T-cell reactions is very rare, it also demands investigation.13,41

4.1.2 – Sulfonamides: Sulfonamides are defined as drugs with a SO2-NH2 moiety. Sulfonamide antibiotics also contain an aromatic amine (N4 position) and a substituted ring (N1 position).40 After βLs, sulfonamide antibiotics (namely sulfamethoxazole-SMX) are the most common cause of DARs.40,42 SMX usually cause cutaneous NIRs and rarely IgE-mediated reactions12,22,44 through the direct activation of T cells by covalent binding or acting as pro-hapten, respectively, as SMX is a chemically inert drug.21,22,43,44 MPE is the most common presentation, but SJSTEN were also described.12,22,40,42

About 40-80% of HIV patients treated with trimethoprim (TMP)-SMX develop a generalized MPE, usually accompanied by fever, while the incidence of skin rashes to TMP-SMX in healthy subjects is only 3% to 5%. The increased risk in HIV patients is probably related to immunologic and metabolic factors and to the frequent exposure to TMP-SMX.42

The N4 aromatic amine is critical for the development of NIRs to sulfonamide antibiotics and the N1 substituted ring appears to be important for IgE-mediated reactions. As non-antibiotic sulfonamides lack these structural components, cross-reactivity with sulfonamide antibiotics is not expected.12,40,42 Conversely, all sulfonamide antibiotics should be considered to be cross-reactive.11

4.1.3 – Fluoroquinolones: This widely used class of broad-spectrum antibiotics can induce reactions mediated by IgE (hapten-carrier formation) and T cells (p-i mechanism).5,45-47 that are estimated to occur in 2% to 3% of the treated patients.45 IgE-mediated reactions are more common and usually severe, with anaphylaxis as the most frequent presentation. Urticaria/angioedema can also occur. NIRs are less frequent and include MPE, FDE, vasculitis, AGEP and SJSTEN.5,45-47 Moxifloxacin induces more severe reactions4 and is the main culprit, followed by ciprofloxacin and levofloxacin.46,48 As cross-reactivity between these antibiotics is common avoidance of all quinolones is advisable.12,48

4.2 – Nonsteroidal anti-inflammatory drugs: NSAIDs are responsible for 21% to 25% of reported ADRs, including immunological and non-immunological reactions. Depending on the clinical presentation and the presumable underlying mechanism, hypersensitivity to NSAIDs is classified in 2 groups and 5 subgroups (Table 2).49 In the first group (≥ 75% of cases), the putative mechanism is the inhibition of cyclooxygenase-1, hence hypersensitivity to multiple NSAIDs is observed regardless of their chemical structure and/or anti-inflammatory potency.49

The second group involves the selective reactions, probably with an underlying immunological mechanism: a) IgE-mediated is the proposed mechanism in cases of urticaria, angioedema and anaphylaxis induced by a single NSAID or a group of chemically related drugs.49,50 Pyrazolones, paracetamol, ibuprofen, diclofenac and naproxen are the most common.49 The last three compounds have a heteroaryl acetic group, presumably carrying a higher risk of anaphylaxis (OR 19.7).51 b) NIRs, probably T-cell mediated, were also reported to be induced by a single NSAID or a group of chemically related drugs.49,51 Cutaneous reactions, particularly MPE are the most frequent reaction. NSAIDs are the main cause of FDE and can also induce SJSTEN (particularly oxicsams).49

Diagnostic and management guidelines for children and adolescents with NSAIDs hypersensitivity, including a modified classification, were recently published considering specific clinical and epidemiological features.52

4.3 – Neuromuscular blocking agents (NMBAs): Immediate HRs during the perioperative period have been increasingly reported.53 Most are mediated by IgE and less frequently related to direct stimulation of histamine release.53-55

IgE mechanism causes perioperative anaphylaxis (estimated incidence of 1:10 000 to 1:20 000) and any drug administered in this period can potentially induce it.53 Different populations exhibit different patterns of sensitization.7 NMBAs are the most common cause in Europe (≥ 75% of cases), 6 the putative mechanism is the inhibition of ciclooxigenase-1, hence hypersensitivity to multiple NMBAs is observed regardless of their chemical structure and/or anti-inflammatory potency.53

Suxamethonium is the most frequent reported culprit, with a recent increment of rocuronium, vecuronium and pancuronium.53,56,57 Sensitization to NMBAs seems to demand the presence of a substituted ammonium ion. In many cases, the reaction may occur at the first exposure, since a prior sensitization to another compound with a substituted ammonium ion (e.g. pholcodine) may have occurred.5,54,55,57

Investigation of cross-reactivity between NMBAs is mandatory in diagnostic work-up.58-62
A new mast cell receptor MRGPRX2 (human Mas-related G-protein-coupled receptor member X2) was discovered and related with reactions to NMBAs not IgE-mediated, which could explain the cases of perioperative anaphylaxis with negative skin testing (mast cell direct activation through this receptor).

4.4 – Radiocontrast media: In the past the ionic high-osmolar RCM induced a high incidence of IRs due to the nonspecific release of vasoactive mediators. Despite the introduction of nonionic (NI) low-osmolar RCM, hypersensitivity reactions (HSRs) are still a matter of concern. A recent European multicenter study suggests that at least 50% of the HRs to NI-RCM are caused by an immunological mechanism. Cross-reactivity was frequent among NI-RCM with a very similar chemical structure. It is estimated that NI-RCM can cause IRs and NIRs in about 1% - 3% of applications. IRs are mainly anaphylaxis, whereas NIRs predominantly manifest as mild skin eruptions occurring hours to days after RCM administration.

4.5 – Biological modifiers: The biologic agents have been recently developed and are increasingly used. They comprise proteins such as cytokines and monoclonal antibodies (mAbs) that differ from other drugs as they have high molecular-weight with a great immunogenic potential. Three major groups of mAbs are in use: chimeric (-ximab), humanized (-zumab) and human antibodies (-mumab). They can induce reactions through different immunological mechanisms. Clinical phenotypes include IRs (type I; infusion-related reactions, cytokine release, mixed reactions), type III and type IV delayed reactions.

IgE-mediated reactions to basiliximab, infliximab and rituximab have been reported. IgE antibodies to cetuximab specifically for alpha-1,3-galactose have been found in the majority of anaphylactic reactions. Rare delayed anaphylaxis has been reported after exposures to omalizumab, trastuzumab, daclizumab, infliximab and basiliximab.

Some patients present IgG antibodies to biologics that may block the effect of the drug or be involved in the development of HSRs. NIRs are rare but have been described, after rituximab (vasculitis, SSS) and infliximab (SSS, SJS, DiHS). Desensitization allows a safe reintroduction of first-line biologic agent.

4.6 – Antineoplastic agents: HSRs to antineoplastic agents are an increasing problem. Any cytostatic can potentially expose the patient to the risk of an immune reaction. They can elicit either immediate (urticaria, bronchospasm, dyspnea, thoracic/abdominal pain, fever, anaphylaxis) or NIRs (maculopapular exanthema, fixed drug eruption, Stevens-Johnson syndrome, toxic epidermal necrolysis; COX-1: Ciclooxigenase 1; IgE: Immunoglobulin E).

Table 2 - Classification of Hypersensitivity Reactions Induced by NSAIDs (adapted from 55)

<table>
<thead>
<tr>
<th>Type of reaction</th>
<th>Clinical manifestations</th>
<th>Timing of reaction</th>
<th>Underlying disease</th>
<th>Cross-reactivity</th>
<th>Presumable mechanism</th>
</tr>
</thead>
<tbody>
<tr>
<td>NSAID-exacerbated respiratory disease (NERD)</td>
<td>Bronchospasm Nasal symptoms</td>
<td>Asthma rhinosinusitis</td>
<td>Cross-reactive</td>
<td>Presumably allergic</td>
<td>COX-1 inhibition</td>
</tr>
<tr>
<td>NSAID-exacerbated cutaneous disease (NECD)</td>
<td>Urticaria and/or angioedema</td>
<td>Acute (usually immediate to several hours after exposure)</td>
<td>Chronic urticaria</td>
<td>Non-reactive</td>
<td>Unknown (probably COX-1 inhibition)</td>
</tr>
<tr>
<td>NSAID-induced urticaria/angioedema (NIUA)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Single NSAID-induced urticaria/angioedema or anaphylaxis (SNIUAA)</td>
<td>Urticaria and/ or angioedema/ anaphylaxis</td>
<td>No underlying chronic disease</td>
<td>IgE-mediated</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Single NSAID-induced delayed reactions (SNIDR)</td>
<td>Various symptoms and organs involved (eg. MPE, FDE, SJS/TEN, nephritis)</td>
<td>Delayed onset (usually &gt; 24h after exposure)</td>
<td>T cell-mediated</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

NSAID: Nonsteroidal anti-inflammatory drug; MPE: Maculopapular exanthema; FDE: Fixed drug eruption; SJS: Stevens-Johnson syndrome; TEN: Toxic epidermal necrolysis; COX: 1: Ciclooxigenase 1; IgE: Immunoglobulin E.
Most reactions occur during the treatment (platinum derivatives and taxanes), although some appear hours after. Reactions to taxanes usually manifest during the first few minutes of the first or second infusion, whereas acute reactions to platinum agents usually occur after several cycles.  

Since these drugs are usually the first line therapy, patients can be desensitized when no equally effective alternative drugs are available. The desensitization should follow the general considerations for these procedures published in a consensus paper for IRs and NIRs.

CONCLUSION

This exhaustive review, although the limitation of being non-systematic, pointed out that despite all advances, drug allergy is not yet fully established and understood. An exceptional contribution was brought by pharmacogenomics, even though a specific association has only been defined for a very limited number of drugs. Further investigation is needed to obtain clearer answers when managing each individual case of DA. The development of new biomarkers and a ‘tailored-made’ medicine is probably the future.

As knowledge in this field moves forward, new updates will be required.

CONFLICTS OF INTEREST

The authors declare they do not have any conflicts of interest and that they did not receive any financial support.